MARKET

NGNE

NGNE

Neurogene
NASDAQ
20.13
-1.29
-6.00%
Opening 15:18 03/27 EDT
OPEN
21.32
PREV CLOSE
21.41
HIGH
21.32
LOW
19.50
VOLUME
89.31K
TURNOVER
--
52 WEEK HIGH
37.27
52 WEEK LOW
6.88
MARKET CAP
313.43M
P/E (TTM)
-4.7503
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) and Sarepta Therapeutics (SRPT)
TipRanks · 1d ago
Buy Rating Backed by Strong NGN-401 Clinical Progress, De-Risking Efficacy Data, and Solid Cash Runway in Rett Syndrome
TipRanks · 1d ago
Buy Rating Underpinned by De-Risked NGN‑401 Development, Aligned Manufacturing Strategy, and Cash Runway Through Key 2027–28 Catalysts
TipRanks · 2d ago
Neurogene Advances Rett Gene Therapy Toward BLA With Strong Cash Runway
TipRanks · 2d ago
1 Top Stock to Buy Now with 350% Upside, 3/24/2026, According to Top Analysts
TipRanks · 3d ago
Midday Fly By: Estee Lauder in deal talks with Puig, Smithfield reports Q4 beat
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Neurogene (NGNE)
TipRanks · 3d ago
Analysts Conflicted on These Healthcare Names: Rezolute (RZLT), Celcuity (CELC) and Neurogene (NGNE)
TipRanks · 3d ago
More
About NGNE
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

Webull offers Neurogene Inc stock information, including NASDAQ: NGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NGNE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NGNE stock methods without spending real money on the virtual paper trading platform.